Skip to main contentSkip to footer
HTA & Reimbursement Strategy

Market Access and Reimbursement

We are health economics consultants who provide end-to-end market access and reimbursement advisory services to support funding across PBS, MBS and Prescribed List pathways.

Connect With An Access Strategist →

Supporting reimbursement decisions in complex HTA environments

This service supports decisions about reimbursement pathways, evidence positioning, pricing strategy and timing of market entry across PBS, MBS and Prescribed List pathways.

These decisions are typically made under conditions of uncertainty, evolving HTA standards and committee judgement — so how evidence is framed and interpreted can be as important as the evidence itself.

Select a pathway below to explore our detailed FAQs and navigate the Australian HTA landscape with confidence:

PBAC Submission FAQs

MSAC Submission FAQs

Prescribed List FAQs

Explore detailed HTA submission pathways

PBAC Submission FAQs

Navigate PBS reimbursement requirements, comparator selection, economic evaluation and PBAC committee expectations.

MSAC Submission FAQs

Understand MBS funding pathways, evidence standards, clinical utility and MSAC evaluation frameworks.

Prescribed List FAQs

Strategic guidance for medical device reimbursement, benefit categories and private payer positioning.

Decision-ready reimbursement strategy and advisory

Pulse Economics helps pharmaceutical, biotech, medtech and diagnostics sponsors navigate market access and reimbursement pathways with clarity.

Our advice is shaped by first-hand PBAC and MSAC submission evaluation experience, meaning we understand not only what is required, but how submissions are assessed in practice.

We work with clients to anticipate committee concerns, clarify trade-offs and design strategies that are robust to evaluation and policy scrutiny.

Market access support in practice

PBAC, MSAC and Prescribed List pathway strategy

Reimbursement pathway assessment aligned to funding and HTA objectives.

Comparator, endpoint and PICO strategy

Decision-focused evidence positioning designed for PBAC/MSAC evaluation scrutiny.

Submission drafting and review

Submission design, drafting, critique and response to evaluation issues.

Reimbursement and payer positioning

Positioning across public and private reimbursement environments.

Pre-submission and post-decision support

Advice across all phases of the reimbursement lifecycle.

Tailored evidence interpretation

All deliverables are adapted to the product maturity and evidence base.

Built for real-world committee decision-making

01

Evaluator-informed

Grounded in experience assessing PBAC and MSAC submissions.

02

Decision-focused

Built for evidence-based committee deliberation.

03

Integrated

Linking clinical evidence, economic modelling and policy context.

04

Pragmatic

Recognising uncertainty, constraints and real-world market access trade-offs.

Relevant across the full product lifecycle

Early Development and Pathway Planning

Pre-submission Strategy and Evidence Positioning

Initial and Resubmission Support

Post-decision Strategy and Lifecycle Management

Independent advice grounded in real HTA evaluation

Direct PBAC and MSAC evaluation experience

First-hand insight into how committees assess evidence and submissions.

Commercialisation and reimbursement understanding

Expertise across Australian reimbursement, policy and committee processes.

Strong evidence and modelling integration

Linking evidence strategy, economic modelling and reimbursement positioning.

Clear and defensible strategic advice

Grounded in how real-world committee decisions are actually made.

Explore how we can support your market access pathway

Successful reimbursement outcomes begin with evidence, positioning and decision frameworks designed for real HTA scrutiny.

Connect With An Access Strategist →

Frequently Asked Questions

It covers the full journey from pathway strategy to a funding decision: working out the most appropriate reimbursement pathway, building the comparator and evidence position, drafting and reviewing the submission, then supporting sponsors through payer positioning and any resubmission.
It comes down to what’s being funded. Medicines generally go through PBAC for PBS listing. Medical services and many diagnostic tests go through MSAC for MBS funding. Medical devices and human tissue products are assessed for the Prescribed List, with advice from MDHTAC. Some products need more than one pathway, so pathway strategy is usually the first thing to get right, before evidence generation locks in a direction.
PICO stands for Population, Intervention, Comparator and Outcomes. MSAC formally confirms a PICO before an application is assessed. PBAC submissions are built around the same elements. Getting the comparator or outcome definitions wrong at this stage is one of the most common reasons a submission runs into committee pushback later.
A rejection or deferral isn’t the end of the process. Many submissions go through more than one cycle before they’re recommended. What matters is understanding exactly what the committee’s concerns were, using the Public Summary Document and committee feedback, then building a resubmission that addresses them directly rather than resubmitting largely the same evidence.
Someone who has evaluated PBAC or MSAC submissions has seen first-hand how they get picked apart, which is different from knowing the guidelines on paper. Three of our team are former PBAC and MSAC evaluators, so our advice is shaped by evaluation experience.
The Prescribed List sets the benefits private health insurers pay for listed medical devices and human tissue products. Following the reforms, applications follow one of several assessment pathways depending on the product and its evidence, with advice from MDHTAC. We help medtech companies choose the right pathway, build the clinical and economic evidence and prepare applications that meet current expectations.